Skip to main content
Evidence Snapshot

GABA-A receptor; anion channel

CHEMBL1907607 PROTEIN COMPLEX GROUP Rattus norvegicus
Source Header

ChEMBL 36 via Core Engine

Target Snapshot 2026-09-13T20:45:11Z
Source · ChEMBL 36 via Core Engine
ChEMBL ChEMBL 36 CHEMBL1907607
Identity Layer

Cross-source identity

Keep the review anchor, source IDs, and context contract aligned before reusing this target elsewhere.

This review treats GABA-A receptor; anion channel as ChEMBL target CHEMBL1907607, mapped to UniProt O09028. Disease framing currently uses the Open Targets-ready proxy contract.

Review anchor
GABA-A receptor; anion channel
PROTEIN COMPLEX GROUP · Rattus norvegicus
As of 2026-09-13
ChEMBL target ID
CHEMBL1907607
Primary anchor for compounds, assays, approvals, and exports
ChEMBL 36 via Core Engine As of 2026-09-13
www.ebi.ac.uk
UniProt accession
O09028
Gamma-aminobutyric acid receptor subunit pi
UniProt accession via ChEMBL component mapping As of 2026-09-13
www.uniprot.org
Disease evidence contract
Open Targets-ready proxy
ChEMBL drug mechanism + indication proxy
ChEMBL drug mechanism + indication proxy As of 2026-09-13
www.ebi.ac.uk

Reuse the same identifiers in notes, watch rules, exports, and review packs so provenance stays stable across surfaces.

Review-ready Target Rationale

Why GABA-A receptor; anion channel matters

As of 2026-09-13

GABA-A receptor; anion channel is reviewed as Gamma-aminobutyric acid receptor subunit pi (UniProt O09028); the current evidence base includes 28 approved drugs, 3354 compounds, and 548 assays, with lead potency reaching pChEMBL 10.3.

Protein context
Gamma-aminobutyric acid receptor subunit pi

Gamma-aminobutyric acid receptor subunit pi Sequence length is 440 aa.

Review this target as GABA-A receptor; anion channel, mapped to UniProt O09028. ChEMBL maps the protein component as Gamma-aminobutyric acid receptor subunit pi. Sequence length is 440 aa.

Protein source · UniProt accession via ChEMBL component mapping
UniProt O09028 Protein
Disease context
Disease signal

Disease relevance is not yet populated for this evidence card.

This disease block keeps the Open Targets-ready contract explicit while current evidence comes from ChEMBL mechanism and indication mappings.

ChEMBL target record
Activity base
Portfolio and assay base

ChEMBL currently tracks 28 approved drugs, 3354 compounds, and 548 assays for this target. The dominant activity type is IC50. CHEMBL380906 is the current potency anchor at pChEMBL 10.3.

Use CHEMBL380906 as the tractability anchor when discussing potency (pChEMBL 10.3).

Activity source · ChEMBL 36 via Core Engine
28 approved pChEMBL 10.3
Source Guidance

Start with the right source

Pick the first block or linked source that matches the review question in front of you.

Need the shortest review narrative first?
Review-ready Target Rationale
One-page rationale with as-of-date and attribution

Start with the review rationale when you need to explain why GABA-A receptor; anion channel matters before drilling into raw source blocks.

Jump to Review Rationale
Need stable protein naming or accession mapping?
UniProt Target Context
UniProt accession via ChEMBL component mapping

Go back to the target snapshot when you need the naming and mapping contract behind UniProt O09028, not just the summarized rationale.

Open Protein Context
Need disease fit or evidence level for program framing?
Disease Relevance & Evidence Level
ChEMBL drug mechanism + indication proxy

Use the target snapshot disease block when you need the disease program and supporting signals, not only the card summary.

Open Disease Context

Snapshot State

No project snapshot selected. Export uses the live evidence card state.

3354
Total Compounds
548
Total Assays
28
Approved Drugs
IC50: 2364.0, KI: 1497.0, EC50: 16.0, KD: 33.0
Activity Types

pChEMBL Activity Distribution

Top 5 Inhibitors (by pChEMBL)

Structure Compound pChEMBL Type Phase
No preferred name
CHEMBL380906
10.3 Ki
No preferred name
CHEMBL3144615
10.3 Ki
No preferred name
CHEMBL3144841
10.1 Ki
10.0 Ki
10.0 IC50

Approved Drugs

Structure Compound First Approval
ZURANOLONE
CHEMBL4105630
2023
GANAXOLONE
CHEMBL1568698
2022
BREXANOLONE
CHEMBL207538
2019
ZOLPIDEM
CHEMBL911
1992
FLUMAZENIL
CHEMBL407
1991
CLARITHROMYCIN
CHEMBL1741
1991
1987
1986
MIDAZOLAM
CHEMBL655
1985
ALPRAZOLAM
CHEMBL661
1981
TRIAZOLAM
CHEMBL646
1978
BACLOFEN
CHEMBL701
1977
CLONAZEPAM
CHEMBL452
1975
DIAZEPAM
CHEMBL12
1963
1960
ALPIDEM
CHEMBL54349
ZOPICLONE
CHEMBL135400
FLUNITRAZEPAM
CHEMBL13280
← Target Page
Source Header

ChEMBL 36 via Core Engine

Target Snapshot 2026-09-13T20:45:11Z
Source · ChEMBL 36 via Core Engine
ChEMBL ChEMBL 36 CHEMBL1907607